0HL9 Affimed N.V.

Partial data

LSE · GB · Healthcare · Biotechnology · affimed.com

0.0001USD0.00%Mkt Cap: —P/E: —26d ago

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has comple…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$129.20BUSDP/E 29.7

MRNA

Moderna, Inc. - Common Stock

$89.83BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$76.86BUSDP/E 18.5

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

$40.67BUSD

ONC

BeOne Medicines Ltd. - American Depositary Shares

$40.33BUSDP/E 63.4

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$32.90BUSDP/E 30.3

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$31.13BUSDP/E 39.2

ROIV

Roivant Sciences Ltd. - Common Shares

$25.60BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.36BUSD

INCY

Incyte Corporation - Common Stock

$22.86BUSDP/E 14.4

GMAB

Genmab A/S - American Depositary Shares

Insmed Incorporated - Common Stock

$21.97BUSD

ASND

Ascendis Pharma A/S - Ordinary Share

$15.08BUSDP/E 17.6

EXEL

Exelixis, Inc. - Common Stock

$14.83BUSDP/E 18.9

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$14.18BUSDP/E 15.0

SMMT

Summit Therapeutics Inc. - Common Stock

$14.03BUSD

Key Statistics

Company

Market Cap—

Enterprise Value-11.21M USD

Revenue (TTM)5.64M USD

Gross Profit5.64M USD

Net Income (TTM)-69.97M USD

Revenue/Share0.37 USD

Last Price0.0001 USD

Fiscal Year EndDec 2023

MR QuarterSep 2024

Employees76

CountryGB

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA0.18

EV/Revenue-1.99

P/S—

P/B0.00

EPS (TTM)-0.66

EPS (Forward)—

52W Range

0.00000% of range1.200

52W High1.200 USD

52W Low0.0000 USD

Profitability

Gross Margin100.00%

Oper. Margin-8709.15%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-149.49%

ROA-49.42%

Growth

Revenue Growth-91.60%

Earnings Growth—

Cash Flow & Leverage

Operating CF-76.90M USD

CapEx (TTM)—

FCF Margin-805.14%

FCF Yield—

Net Debt-11.21M USD

Net Debt/EBITDA0.18

Balance Sheet

Debt/Equity74.96

Current Ratio1.93

Quick Ratio1.71

Book Value/Sh1.20 USD

Cash/Share1.47 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Splits

Last Split0.1:1

Split DateMar 11, 2024

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.—

Float15.48M

Insiders0.00%

Institutions0.00%

Technical

SMA 505.510 (-100.0%)

SMA 2005.863 (-100.0%)

Beta0.31

S&P 52W Chg14.88%

Avg Vol (30d)1.11K

Avg Vol (10d)1.15K

Technical Indicators

RSI (14)47.8

MACD-0.0000

MACD Signal-0.0000

MACD Hist.+0.0000

BB Upper0.0002 USD

BB Middle0.0001 USD

BB Lower0.0000 USD

BB Width162.08%

ATR (14)0.0000 USD

Vol Ratio (20d)0.26x